Good morning :)
$
₹
Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

IRWD

NASDAQ
Asset Logo

Ironwood Pharmaceuticals Inc

IRWD

NASDAQ
$3.972.38% (-0.09)
$
₹
$3.972.38% (-0.09)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Drug Manufacturers - Specialty & Generic

Small Cap

With a market cap of $689.1M the stock is ranked 3113

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

5.27
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

2.58
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$0.79
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

-0.26
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

33.36%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 4 analysts' reports

Buy
0 analyst
Hold
4 analysts
Sell
0 analyst

Analysts expect a +49.88% price upside over the next year

Current Price$3.97
Target Price$6.1

Company Profile

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Peers

Peers

AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
70.27
70.27
1Y Return
19.4%
19.4%
Buy Reco %
57.14
57.14
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
24.43
24.43
1Y Return
41.48%
41.48%
Buy Reco %
46.87
46.87
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
27.25%
27.25%
Buy Reco %
63.33
63.33
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
30.83
30.83
1Y Return
32.43%
32.43%
Buy Reco %
52.94
52.94
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
20.06
20.06
1Y Return
42.89%
42.89%
Buy Reco %
76.00
76.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - Specialty & Generic

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Ironwood Pharmaceuticals Inc 5.272.58-0.26
AbbVie Inc70.2750.450.36
Amgen Inc24.4320.222.10

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

122
40
47.7
-2.2
106.5
40.7
113
51.2
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue74.8794.3991.5990.5441.1485.23122.0647.70106.50113.04
Net Income-4.16-0.863.642.25-37.3823.5940.08-2.2740.7751.29
Net Profit Margin-5.55%-0.91%3.98%2.49%-90.86%27.68%32.83%-4.77%38.28%45.37%
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Ironwood Pharmaceuticals Inc (IRWD) share price today is $3.97 as of September 11, 2026 at 1:30 AM IST. The stock touched a day high of $4.02 and a day low of $3.94.

  2. Ironwood Pharmaceuticals Inc stock trades on NASDAQ under the ticker symbol IRWD.

  3. Ironwood Pharmaceuticals Inc's market capitalization is $689.05M as of September 11, 2026 at 1:30 AM IST.

  4. Ironwood Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 5.27 as of September 10, 2026.

  5. Ironwood Pharmaceuticals Inc's price-to-book (P/B) ratio is 2.58 as of September 10, 2026.

  6. Yes, You can buy Ironwood Pharmaceuticals Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Ironwood Pharmaceuticals Inc shares in three steps: 1. Search Ironwood Pharmaceuticals Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Ironwood Pharmaceuticals Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Ironwood Pharmaceuticals Inc (IRWD) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 2.5169 shares at the current price of $3.97.

Loading...